Anti-PD-1 treatment resulted in similar phenotypes in both genotypes of T cells: increased proportions of CD44 + CD62L− cells in tumors at later timepoints, a more rapid progression to the TCF1low phenotype in the tumor, and a trend for more Ki67 expression in TCF1high cells in the tumor at the latest timepoint. Here, SELL is linked to neoplasm.